培美曲塞治疗晚期非小细胞肺癌临床观察  

Clinical observation of pemetrexed on treating advanced non-small cell lung cancer

作　　者：邬仁华[1] 伍建蓉[1] 郑玲[1] 谷焰[1] 

机构地区：[1]成都大学附属医院肿瘤科,四川成都610000

出　　处：《现代医药卫生》2011年第17期2567-2568,共2页Journal of Modern Medicine & Health

摘　　要：目的:观察培美曲塞联合铂类治疗晚期非小细胞肺癌的疗效及不良反应。方法:选择经病理学证实的非小细胞肺癌患者10例,培美曲塞500 mg/m2,第一天静脉滴注,常规剂量联合顺铂或卡铂或奥沙利铂,21天为1周期,每例患者至少化疗2周期。评价疗效及不良反应。结果:完全缓解(CR)0例(0%),部分缓解(PR)3例(30%),稳定(SD)4例(40%),进展(PD)3例(30%),总有效率为30%,疾病控制率为70%。主要不良反应为骨髓抑制、胃肠道反应及贫血。结论:培美曲塞治疗晚期非小细胞肺癌疗效确切,不良反应小。Objective：To observe the efficacy and toxicity of pemetrexed combined with platinum for treating advanced non-small cell lung cancer（NSCLC）.Methods：10 patients diagnosed as NSCLC were treated with pemetrexed 500 mg/m2 by intravenous drip on 1 d with 21 d as one cycle,combined with cisplatin or carboplatin or oxaliplatin in routine dose.Two cycles were needed at least.The efficacy and adverse reactions were evaluated.Results：There was no case of complete remission（CR）,2 cases of partial remission（PR）,4 cases of stable disease（SD） and 3 cases of progressive disease（PD） in this group.The overall response rate was 30.0% and the disease control rate was 70.0%.The major toxic reactions included bone marrow depression,nausea and vomiting and anemia.Conclusion：Chemotherapy with pemetrexed in the treatment of advanced non-small cell lung cancer is effective,safe and well-tolerable with less adverse reactions.

关 键 词：培美曲塞 非小细胞肺癌 化疗 

分 类 号：R73[医药卫生—肿瘤]